Serum metabolic alterations associated with Chaihu-Longgu-Muli decoction in adolescents with insomnia: An exploratory untargeted metabolomics study
- 1Department of Traditional Chinese Medicine, Hainan Women and Children’s Medical Center, Haikou, China
- 2Graduate School of Heilongjiang University of Chinese Medicine, Harbin, China
- 3Department of Geriatrics, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Abstract
Adolescent insomnia is common and is frequently accompanied by anxiety and depressive symptoms. Chaihu-Longgu-Muli decoction (CLMD) is used in traditional Chinese medicine prescriptions for insomnia; however, the biological changes associated with CLMD treatment in adolescents remain poorly characterized. This exploratory study investigated clinical symptom changes and corresponding serum metabolomic alterations associated with CLMD treatment in adolescents with chronic insomnia. Adolescents with chronic insomnia received either CLMD or cognitive behavioral therapy (CBT) according to the predefined treatment-allocation procedure. A healthy control group was included for baseline metabolic comparison. Sleep quality and emotional symptoms were assessed using the Pittsburgh Sleep Quality Index (PSQI), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS). Fasting serum samples collected before and after the intervention underwent untargeted metabolomic profiling using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Candidate differential metabolites were identified using multivariate analysis together with a variable importance in projection score > 1.0 and nominal P < .05, followed by pathway enrichment analysis. Given the exploratory nature of the study, metabolomic findings were considered hypothesis-generating. Thirty adolescents were included in each intervention group, with an additional 10 healthy controls. Both CLMD and CBT groups showed improvements in PSQI, SAS, and SDS measures after treatment (all P < .05). Untargeted metabolomic profiling identified differences between adolescents with insomnia and healthy controls. Among the exploratory candidate metabolites, sphinganine and 3-indoleacetonitrile were higher in adolescents with insomnia, whereas ethylmethylacetic acid, choline, L-lysine 1,6-lactam, (R)-2-O-sulfolactate, cis-aconitic acid, and sorbitol were lower (all P < .05). Following CLMD treatment, these metabolites shifted toward levels observed in healthy controls. Exploratory pathway analysis implicated the intestinal immune network for IgA production, sphingolipid signaling, PPAR signaling, and bile secretion. CLMD treatment was associated with improvements in insomnia-related symptoms and concurrent changes in serum metabolic profiles in adolescents with chronic insomnia. The identified metabolites and pathways represent preliminary biological signals rather than validated biomarkers or established mechanisms. Larger studies with targeted quantitative metabolomics and independent validation are needed.
Related
- Cerebrospinal fluid metabolite alterations associated with human brain aging: an untargeted metabolomics study
- Exploratory Untargeted Plasma Lipidomics Suggests Subtype-Associated Lipid Alterations in Hereditary Hemolytic Anemias
- Untargeted Metabolomics via UPLC-HRMS and ASCA-Based Statistical Modeling to Characterize Metabolic Alterations Following Acute and Repeated Brorphine Exposure
- Untargeted metabolomics reveals a reproducible signature associated with fatal insulin intoxication
- Composite metabolic indices for the assessment of early biochemical and metabolic alterations in Iraqi children and adolescents with type 1 diabetes: an exploratory case–control study
BibTeX
@article{xu2026serum,
title = {{Serum metabolic alterations associated with Chaihu-Longgu-Muli decoction in adolescents with insomnia: An exploratory untargeted metabolomics study}},
author = {Hong-yun Xu and Tian-wei Meng and Rui Zhao and Hong-mei Huo and Yu-jing Fu and Xin-yu Wu and Jing-han Huang and Rui Qie},
journal = {Medicine},
year = {2026},
month = nov,
doi = {10.1097/md.0000000000051296},
url = {https://doi.org/10.1097/md.0000000000051296},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Serum metabolic alterations associated with Chaihu-Longgu-Muli decoction in adolescents with insomnia: An exploratory untargeted metabolomics study
AU - Hong-yun Xu
AU - Tian-wei Meng
AU - Rui Zhao
AU - Hong-mei Huo
AU - Yu-jing Fu
AU - Xin-yu Wu
AU - Jing-han Huang
AU - Rui Qie
PY - 2026
DA - 2026/11/06
JO - Medicine
DO - 10.1097/md.0000000000051296
UR - https://doi.org/10.1097/md.0000000000051296
AB - Adolescent insomnia is common and is frequently accompanied by anxiety and depressive symptoms. Chaihu-Longgu-Muli decoction (CLMD) is used in traditional Chinese medicine prescriptions for insomnia; however, the biological changes associated with CLMD treatment in adolescents remain poorly characterized. This exploratory study investigated clinical symptom changes and corresponding serum metabolomic alterations associated with CLMD treatment in adolescents with chronic insomnia. Adolescents with chronic insomnia received either CLMD or cognitive behavioral therapy (CBT) according to the predefined treatment-allocation procedure. A healthy control group was included for baseline metabolic comparison. Sleep quality and emotional symptoms were assessed using the Pittsburgh Sleep Quality Index (PSQI), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS). Fasting serum samples collected before and after the intervention underwent untargeted metabolomic profiling using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Candidate differential metabolites were identified using multivariate analysis together with a variable importance in projection score > 1.0 and nominal P < .05, followed by pathway enrichment analysis. Given the exploratory nature of the study, metabolomic findings were considered hypothesis-generating. Thirty adolescents were included in each intervention group, with an additional 10 healthy controls. Both CLMD and CBT groups showed improvements in PSQI, SAS, and SDS measures after treatment (all P < .05). Untargeted metabolomic profiling identified differences between adolescents with insomnia and healthy controls. Among the exploratory candidate metabolites, sphinganine and 3-indoleacetonitrile were higher in adolescents with insomnia, whereas ethylmethylacetic acid, choline, L-lysine 1,6-lactam, (R)-2-O-sulfolactate, cis-aconitic acid, and sorbitol were lower (all P < .05). Following CLMD treatment, these metabolites shifted toward levels observed in healthy controls. Exploratory pathway analysis implicated the intestinal immune network for IgA production, sphingolipid signaling, PPAR signaling, and bile secretion. CLMD treatment was associated with improvements in insomnia-related symptoms and concurrent changes in serum metabolic profiles in adolescents with chronic insomnia. The identified metabolites and pathways represent preliminary biological signals rather than validated biomarkers or established mechanisms. Larger studies with targeted quantitative metabolomics and independent validation are needed.
SN - 0025-7974
SN - 1536-5964
ER -